Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal
Arrowhead Pharmaceuticals shifts focus to subcutaneous platform after abandoning lead hepatitis B program and related products due to toxicity concerns, resolving to lay off 30% of staff.
You may also be interested in...
The pharma is paying $250m up front for worldwide rights to Arrowhead’s Phase I/II RNAi candidate. Arrowhead says letting J&J take the lead on HBV enables it to focus on other pipeline programs it can bring to market itself.
Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.
With recent product approvals and the development of new chemistries and delivery technologies, the RNA-based drugs sector is undergoing rapid change, and UK-based Silence Therapeutics is aiming to be part of that evolution.